Compare ACOG & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ACOG | FATE |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 115.5M | 124.6M |
| IPO Year | N/A | 2013 |
| Metric | ACOG | FATE |
|---|---|---|
| Price | $5.67 | $1.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $18.00 | $3.92 |
| AVG Volume (30 Days) | 76.2K | ★ 1.7M |
| Earning Date | 11-13-2025 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,427,199.00 | $7,137,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $132.35 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.75 | $0.66 |
| 52 Week High | $11.54 | $1.94 |
| Indicator | ACOG | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 42.26 | 64.97 |
| Support Level | $5.20 | $1.02 |
| Resistance Level | $6.04 | $1.22 |
| Average True Range (ATR) | 0.44 | 0.08 |
| MACD | -0.08 | 0.03 |
| Stochastic Oscillator | 28.02 | 91.43 |
Alpha Cognition Inc is a biopharmaceutical company dedicated to developing treatments for patients suffering from neurodegenerative diseases, such as Alzheimer's disease, for which there are limited or no treatment options. The Company's current focus is on the commercial manufacturing and sales of ZUNVEYL oral tablet formulation. The Company's commercial development program for ZUNVEYL is primarily focused on building a long-term care commercial team that can focus on providing key points of differentiation, exploiting key issues with existing Acetylcholinesterase inhibitors treatments, and seeking potential licensing partners for other additional indications and new formulations.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.